nodes	percent_of_prediction	percent_of_DWPC	metapath
Naloxone—OPRM1—autistic disorder	0.659	1	CbGaD
Naloxone—CREB1—telencephalic ventricle—autistic disorder	0.0125	0.105	CbGeAlD
Naloxone—TLR4—eye—autistic disorder	0.00749	0.0627	CbGeAlD
Naloxone—OPRM1—telencephalic ventricle—autistic disorder	0.00675	0.0565	CbGeAlD
Naloxone—CREB1—hindbrain—autistic disorder	0.00591	0.0495	CbGeAlD
Naloxone—CREB1—mouth—autistic disorder	0.00519	0.0434	CbGeAlD
Naloxone—TLR4—cerebellum—autistic disorder	0.00379	0.0318	CbGeAlD
Naloxone—CREB1—brainstem—autistic disorder	0.00339	0.0284	CbGeAlD
Naloxone—CREB1—eye—autistic disorder	0.0033	0.0276	CbGeAlD
Naloxone—CREB1—forebrain—autistic disorder	0.00327	0.0274	CbGeAlD
Naloxone—TLR4—brain—autistic disorder	0.00308	0.0258	CbGeAlD
Naloxone—CREB1—telencephalon—autistic disorder	0.00301	0.0252	CbGeAlD
Naloxone—OPRD1—forebrain—autistic disorder	0.00258	0.0216	CbGeAlD
Naloxone—OPRK1—forebrain—autistic disorder	0.00248	0.0207	CbGeAlD
Naloxone—OPRD1—telencephalon—autistic disorder	0.00238	0.0199	CbGeAlD
Naloxone—ESR1—hindbrain—autistic disorder	0.00233	0.0195	CbGeAlD
Naloxone—CREB1—digestive system—autistic disorder	0.0023	0.0192	CbGeAlD
Naloxone—Levallorphan—OPRM1—autistic disorder	0.00194	0.219	CrCbGaD
Naloxone—CREB1—head—autistic disorder	0.00187	0.0157	CbGeAlD
Naloxone—OPRM1—brainstem—autistic disorder	0.00183	0.0153	CbGeAlD
Naloxone—CREB1—nervous system—autistic disorder	0.00178	0.0149	CbGeAlD
Naloxone—OPRM1—forebrain—autistic disorder	0.00176	0.0148	CbGeAlD
Naloxone—CREB1—central nervous system—autistic disorder	0.00171	0.0143	CbGeAlD
Naloxone—CREB1—cerebellum—autistic disorder	0.00167	0.014	CbGeAlD
Naloxone—OPRM1—telencephalon—autistic disorder	0.00162	0.0136	CbGeAlD
Naloxone—SLCO1A2—forebrain—autistic disorder	0.00152	0.0127	CbGeAlD
Naloxone—OPRD1—head—autistic disorder	0.00148	0.0124	CbGeAlD
Naloxone—OPRK1—head—autistic disorder	0.00142	0.0119	CbGeAlD
Naloxone—OPRD1—nervous system—autistic disorder	0.0014	0.0117	CbGeAlD
Naloxone—SLCO1A2—telencephalon—autistic disorder	0.0014	0.0117	CbGeAlD
Naloxone—CREB1—brain—autistic disorder	0.00136	0.0114	CbGeAlD
Naloxone—OPRD1—central nervous system—autistic disorder	0.00135	0.0113	CbGeAlD
Naloxone—OPRK1—nervous system—autistic disorder	0.00135	0.0113	CbGeAlD
Naloxone—ESR1—brainstem—autistic disorder	0.00133	0.0112	CbGeAlD
Naloxone—OPRK1—central nervous system—autistic disorder	0.0013	0.0108	CbGeAlD
Naloxone—ESR1—forebrain—autistic disorder	0.00129	0.0108	CbGeAlD
Naloxone—OPRK1—cerebellum—autistic disorder	0.00127	0.0106	CbGeAlD
Naloxone—ESR1—telencephalon—autistic disorder	0.00118	0.00991	CbGeAlD
Naloxone—Methylnaltrexone—OPRM1—autistic disorder	0.00111	0.126	CrCbGaD
Naloxone—OPRD1—brain—autistic disorder	0.00107	0.00898	CbGeAlD
Naloxone—SLCO1A2—digestive system—autistic disorder	0.00107	0.00892	CbGeAlD
Naloxone—OPRK1—brain—autistic disorder	0.00103	0.00861	CbGeAlD
Naloxone—Nalbuphine—OPRM1—autistic disorder	0.00102	0.115	CrCbGaD
Naloxone—OPRM1—head—autistic disorder	0.00101	0.00845	CbGeAlD
Naloxone—OPRM1—nervous system—autistic disorder	0.000957	0.00801	CbGeAlD
Naloxone—OPRM1—central nervous system—autistic disorder	0.000921	0.00771	CbGeAlD
Naloxone—ESR1—digestive system—autistic disorder	0.000904	0.00756	CbGeAlD
Naloxone—SLCO1A2—head—autistic disorder	0.000869	0.00727	CbGeAlD
Naloxone—Oxymorphone—OPRM1—autistic disorder	0.000831	0.0939	CrCbGaD
Naloxone—Naltrexone—OPRM1—autistic disorder	0.000831	0.0939	CrCbGaD
Naloxone—SLCO1A2—nervous system—autistic disorder	0.000824	0.00689	CbGeAlD
Naloxone—SLCO1A2—central nervous system—autistic disorder	0.000793	0.00664	CbGeAlD
Naloxone—SLCO1A2—cerebellum—autistic disorder	0.000775	0.00649	CbGeAlD
Naloxone—ESR1—head—autistic disorder	0.000737	0.00617	CbGeAlD
Naloxone—OPRM1—brain—autistic disorder	0.000732	0.00612	CbGeAlD
Naloxone—Hydrocodone—OPRM1—autistic disorder	0.000726	0.082	CrCbGaD
Naloxone—ESR1—nervous system—autistic disorder	0.000699	0.00585	CbGeAlD
Naloxone—ESR1—central nervous system—autistic disorder	0.000673	0.00563	CbGeAlD
Naloxone—Oxycodone—OPRM1—autistic disorder	0.000663	0.0749	CrCbGaD
Naloxone—ESR1—cerebellum—autistic disorder	0.000658	0.0055	CbGeAlD
Naloxone—SLCO1A2—brain—autistic disorder	0.00063	0.00527	CbGeAlD
Naloxone—ALB—brain—autistic disorder	0.000626	0.00524	CbGeAlD
Naloxone—Buprenorphine—OPRM1—autistic disorder	0.000611	0.069	CrCbGaD
Naloxone—Hydromorphone—OPRM1—autistic disorder	0.000602	0.068	CrCbGaD
Naloxone—ESR1—brain—autistic disorder	0.000534	0.00447	CbGeAlD
Naloxone—Morphine—OPRM1—autistic disorder	0.000512	0.0578	CrCbGaD
Naloxone—ABCB1—forebrain—autistic disorder	0.000508	0.00425	CbGeAlD
Naloxone—CYP3A4—digestive system—autistic disorder	0.000504	0.00422	CbGeAlD
Naloxone—ABCB1—telencephalon—autistic disorder	0.000468	0.00391	CbGeAlD
Naloxone—CYP2C8—brain—autistic disorder	0.00044	0.00368	CbGeAlD
Naloxone—CYP3A4—nervous system—autistic disorder	0.00039	0.00326	CbGeAlD
Naloxone—CYP3A4—central nervous system—autistic disorder	0.000375	0.00314	CbGeAlD
Naloxone—ABCB1—digestive system—autistic disorder	0.000357	0.00299	CbGeAlD
Naloxone—ABCB1—head—autistic disorder	0.000291	0.00244	CbGeAlD
Naloxone—ABCB1—nervous system—autistic disorder	0.000276	0.00231	CbGeAlD
Naloxone—ABCB1—central nervous system—autistic disorder	0.000266	0.00222	CbGeAlD
Naloxone—ABCB1—cerebellum—autistic disorder	0.00026	0.00217	CbGeAlD
Naloxone—ABCB1—brain—autistic disorder	0.000211	0.00177	CbGeAlD
Naloxone—CREB1—Immune System—BCL2—autistic disorder	1.39e-05	6.57e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—DRD3—autistic disorder	1.39e-05	6.55e-05	CbGpPWpGaD
Naloxone—CREB1—Immune System—IFNG—autistic disorder	1.38e-05	6.51e-05	CbGpPWpGaD
Naloxone—ALB—Hemostasis—PRKCB—autistic disorder	1.37e-05	6.48e-05	CbGpPWpGaD
Naloxone—ALB—Platelet activation, signaling and aggregation—MAPK1—autistic disorder	1.37e-05	6.47e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—DAO—autistic disorder	1.37e-05	6.44e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—IL5—autistic disorder	1.36e-05	6.41e-05	CbGpPWpGaD
Naloxone—ALB—Hemostasis—NOS2—autistic disorder	1.36e-05	6.4e-05	CbGpPWpGaD
Naloxone—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK1—autistic disorder	1.35e-05	6.37e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—HTR2A—autistic disorder	1.34e-05	6.33e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—CALCA—autistic disorder	1.34e-05	6.33e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling by GPCR—IL2—autistic disorder	1.34e-05	6.33e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling by GPCR—POMC—autistic disorder	1.34e-05	6.32e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—HTR2A—autistic disorder	1.34e-05	6.31e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling by GPCR—IL2—autistic disorder	1.34e-05	6.31e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—PRL—autistic disorder	1.34e-05	6.31e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism of lipids and lipoproteins—APOE—autistic disorder	1.33e-05	6.29e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—PLA2G4A—autistic disorder	1.33e-05	6.25e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism of lipids and lipoproteins—APOE—autistic disorder	1.33e-05	6.25e-05	CbGpPWpGaD
Naloxone—ALB—Hemostasis—PIK3CG—autistic disorder	1.32e-05	6.2e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—UPB1—autistic disorder	1.31e-05	6.17e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—RORA—autistic disorder	1.3e-05	6.14e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—TPH2—autistic disorder	1.3e-05	6.14e-05	CbGpPWpGaD
Naloxone—ALB—Hemostasis—EGF—autistic disorder	1.3e-05	6.13e-05	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism—MTHFR—autistic disorder	1.3e-05	6.12e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—TPH2—autistic disorder	1.3e-05	6.11e-05	CbGpPWpGaD
Naloxone—CREB1—Innate Immune System—HRAS—autistic disorder	1.29e-05	6.1e-05	CbGpPWpGaD
Naloxone—OPRK1—GPCR downstream signaling—IL2—autistic disorder	1.29e-05	6.09e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—MEF2C—autistic disorder	1.29e-05	6.08e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—DPYD—autistic disorder	1.28e-05	6.04e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—TSC2—autistic disorder	1.28e-05	6.01e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—DPYD—autistic disorder	1.28e-05	6.01e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—TSC2—autistic disorder	1.27e-05	6e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—ADRB2—autistic disorder	1.27e-05	5.98e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—ITGB3—autistic disorder	1.26e-05	5.93e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—APOE—autistic disorder	1.25e-05	5.89e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—LEP—autistic disorder	1.25e-05	5.89e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—LEP—autistic disorder	1.25e-05	5.87e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—APOE—autistic disorder	1.25e-05	5.87e-05	CbGpPWpGaD
Naloxone—CREB1—Adaptive Immune System—HRAS—autistic disorder	1.24e-05	5.85e-05	CbGpPWpGaD
Naloxone—CREB1—Innate Immune System—IL6—autistic disorder	1.24e-05	5.83e-05	CbGpPWpGaD
Naloxone—CREB1—Immune System—IL2—autistic disorder	1.23e-05	5.78e-05	CbGpPWpGaD
Naloxone—CREB1—Disease—PTGS2—autistic disorder	1.22e-05	5.76e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—MAOB—autistic disorder	1.22e-05	5.76e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—ASMT—autistic disorder	1.22e-05	5.74e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—GSTM5—autistic disorder	1.22e-05	5.74e-05	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism—APOE—autistic disorder	1.21e-05	5.7e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CG—autistic disorder	1.2e-05	5.67e-05	CbGpPWpGaD
Naloxone—ALB—Hemostasis—IGF1—autistic disorder	1.2e-05	5.67e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism of lipids and lipoproteins—PIK3CG—autistic disorder	1.2e-05	5.64e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—AVP—autistic disorder	1.19e-05	5.62e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—CACNA1C—autistic disorder	1.19e-05	5.62e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—IGF2—autistic disorder	1.19e-05	5.6e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—PRL—autistic disorder	1.19e-05	5.59e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—CACNA1C—autistic disorder	1.19e-05	5.59e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—PRKCB—autistic disorder	1.18e-05	5.55e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—HTR2A—autistic disorder	1.17e-05	5.53e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—PRKCB—autistic disorder	1.17e-05	5.53e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling by GPCR—IL2—autistic disorder	1.17e-05	5.53e-05	CbGpPWpGaD
Naloxone—CREB1—Immune System—PTEN—autistic disorder	1.15e-05	5.44e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism of lipids and lipoproteins—POMC—autistic disorder	1.15e-05	5.4e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—SLC25A12—autistic disorder	1.15e-05	5.4e-05	CbGpPWpGaD
Naloxone—ALB—Hemostasis—SERPINE1—autistic disorder	1.14e-05	5.39e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism of lipids and lipoproteins—POMC—autistic disorder	1.14e-05	5.37e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—TPH2—autistic disorder	1.14e-05	5.35e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—PIK3CG—autistic disorder	1.13e-05	5.31e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—APC—autistic disorder	1.13e-05	5.31e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—ADRB2—autistic disorder	1.13e-05	5.3e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—APC—autistic disorder	1.12e-05	5.3e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—PIK3CG—autistic disorder	1.12e-05	5.3e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—PLA2G4A—autistic disorder	1.12e-05	5.28e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—DPYD—autistic disorder	1.12e-05	5.26e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—TSC2—autistic disorder	1.12e-05	5.26e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—EGF—autistic disorder	1.11e-05	5.25e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—SLC19A1—autistic disorder	1.11e-05	5.25e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—EGF—autistic disorder	1.11e-05	5.23e-05	CbGpPWpGaD
Naloxone—OPRM1—GPCR downstream signaling—IL2—autistic disorder	1.09e-05	5.15e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—APOE—autistic disorder	1.09e-05	5.14e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—LEP—autistic disorder	1.09e-05	5.14e-05	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism—PIK3CG—autistic disorder	1.09e-05	5.14e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—MEF2C—autistic disorder	1.09e-05	5.14e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—DHFR—autistic disorder	1.09e-05	5.11e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—DHFR—autistic disorder	1.08e-05	5.08e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—POMC—autistic disorder	1.07e-05	5.06e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—POMC—autistic disorder	1.07e-05	5.04e-05	CbGpPWpGaD
Naloxone—CREB1—Disease—PTEN—autistic disorder	1.07e-05	5.02e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—ITGB3—autistic disorder	1.06e-05	5.01e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—AVP—autistic disorder	1.06e-05	4.98e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—IGF2—autistic disorder	1.05e-05	4.96e-05	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism—POMC—autistic disorder	1.04e-05	4.9e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—CACNA1C—autistic disorder	1.04e-05	4.89e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—IGF1—autistic disorder	1.03e-05	4.86e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—PRKCB—autistic disorder	1.03e-05	4.85e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—IGF1—autistic disorder	1.03e-05	4.85e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling by GPCR—MAPK1—autistic disorder	1.03e-05	4.84e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling by GPCR—MAPK1—autistic disorder	1.02e-05	4.83e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—PLA2G4A—autistic disorder	9.95e-06	4.69e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—ADSL—autistic disorder	9.93e-06	4.68e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—HTR2A—autistic disorder	9.93e-06	4.68e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling by GPCR—IL2—autistic disorder	9.92e-06	4.67e-05	CbGpPWpGaD
Naloxone—ESR1—Gene Expression—SERPINE1—autistic disorder	9.88e-06	4.65e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—PIK3CG—autistic disorder	9.86e-06	4.64e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—APC—autistic disorder	9.86e-06	4.64e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—SERPINE1—autistic disorder	9.81e-06	4.62e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—SERPINE1—autistic disorder	9.77e-06	4.6e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—EGF—autistic disorder	9.74e-06	4.59e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—XDH—autistic disorder	9.74e-06	4.59e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—MEF2C—autistic disorder	9.68e-06	4.56e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—NPAS2—autistic disorder	9.56e-06	4.5e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—STX1A—autistic disorder	9.56e-06	4.5e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—DHFR—autistic disorder	9.45e-06	4.45e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—TSC2—autistic disorder	9.43e-06	4.44e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—ITGB3—autistic disorder	9.43e-06	4.44e-05	CbGpPWpGaD
Naloxone—CREB1—Immune System—MAPK1—autistic disorder	9.39e-06	4.42e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—POMC—autistic disorder	9.38e-06	4.42e-05	CbGpPWpGaD
Naloxone—ALB—Hemostasis—IL2—autistic disorder	9.26e-06	4.36e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—TCN2—autistic disorder	9.24e-06	4.35e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—LEP—autistic disorder	9.23e-06	4.35e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—APOE—autistic disorder	9.23e-06	4.35e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—autistic disorder	9.15e-06	4.31e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism of lipids and lipoproteins—PTGS2—autistic disorder	9.09e-06	4.28e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—IGF1—autistic disorder	9.03e-06	4.25e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling by GPCR—MAPK1—autistic disorder	8.98e-06	4.23e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—ADA—autistic disorder	8.81e-06	4.15e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—HTR2A—autistic disorder	8.8e-06	4.15e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—PRKCB—autistic disorder	8.71e-06	4.1e-05	CbGpPWpGaD
Naloxone—CREB1—Disease—MAPK1—autistic disorder	8.67e-06	4.08e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—SERPINE1—autistic disorder	8.57e-06	4.04e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—CYP19A1—autistic disorder	8.5e-06	4e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—CYP19A1—autistic disorder	8.45e-06	3.98e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—TSC2—autistic disorder	8.36e-06	3.94e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—APC—autistic disorder	8.33e-06	3.92e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—PIK3CG—autistic disorder	8.33e-06	3.92e-05	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism—PTGS2—autistic disorder	8.29e-06	3.9e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling by GPCR—HRAS—autistic disorder	8.25e-06	3.89e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—EGF—autistic disorder	8.24e-06	3.88e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling by GPCR—HRAS—autistic disorder	8.22e-06	3.87e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—LEP—autistic disorder	8.19e-06	3.86e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—APOE—autistic disorder	8.19e-06	3.86e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—RORA—autistic disorder	8.03e-06	3.78e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—autistic disorder	7.98e-06	3.76e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—IL2—autistic disorder	7.94e-06	3.74e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism of lipids and lipoproteins—PTEN—autistic disorder	7.93e-06	3.74e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—POMC—autistic disorder	7.93e-06	3.74e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—IL2—autistic disorder	7.91e-06	3.73e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—COMT—autistic disorder	7.9e-06	3.72e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling by GPCR—IL6—autistic disorder	7.9e-06	3.72e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling by GPCR—IL6—autistic disorder	7.87e-06	3.71e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—GSTP1—autistic disorder	7.86e-06	3.7e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—COMT—autistic disorder	7.86e-06	3.7e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—MAOA—autistic disorder	7.84e-06	3.69e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—GSTP1—autistic disorder	7.82e-06	3.68e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—MAOA—autistic disorder	7.8e-06	3.67e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—PRKCB—autistic disorder	7.72e-06	3.64e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—CAT—autistic disorder	7.65e-06	3.6e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—IGF1—autistic disorder	7.63e-06	3.59e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—CAT—autistic disorder	7.61e-06	3.58e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling by GPCR—MAPK1—autistic disorder	7.59e-06	3.58e-05	CbGpPWpGaD
Naloxone—CREB1—Immune System—HRAS—autistic disorder	7.54e-06	3.55e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—MAOB—autistic disorder	7.53e-06	3.55e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—PTEN—autistic disorder	7.47e-06	3.52e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—PTEN—autistic disorder	7.44e-06	3.51e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—CYP19A1—autistic disorder	7.4e-06	3.49e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—PIK3CG—autistic disorder	7.39e-06	3.48e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—APC—autistic disorder	7.39e-06	3.48e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—EGF—autistic disorder	7.3e-06	3.44e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—SERPINE1—autistic disorder	7.24e-06	3.41e-05	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism—PTEN—autistic disorder	7.23e-06	3.41e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—GSTM1—autistic disorder	7.23e-06	3.4e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—PLA2G4A—autistic disorder	7.23e-06	3.4e-05	CbGpPWpGaD
Naloxone—CREB1—Immune System—IL6—autistic disorder	7.22e-06	3.4e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling by GPCR—HRAS—autistic disorder	7.21e-06	3.4e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—PLA2G4A—autistic disorder	7.18e-06	3.38e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—GSTM1—autistic disorder	7.18e-06	3.38e-05	CbGpPWpGaD
Naloxone—ALB—Hemostasis—MAPK1—autistic disorder	7.08e-06	3.34e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—POMC—autistic disorder	7.03e-06	3.31e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—TPH2—autistic disorder	7e-06	3.3e-05	CbGpPWpGaD
Naloxone—CREB1—Disease—HRAS—autistic disorder	6.96e-06	3.28e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—IL2—autistic disorder	6.94e-06	3.27e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—GPX1—autistic disorder	6.92e-06	3.26e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling by GPCR—IL6—autistic disorder	6.9e-06	3.25e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—DPYD—autistic disorder	6.89e-06	3.24e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—COMT—autistic disorder	6.88e-06	3.24e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—GPX1—autistic disorder	6.88e-06	3.24e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—GSTP1—autistic disorder	6.85e-06	3.23e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—MAOA—autistic disorder	6.83e-06	3.22e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—IGF1—autistic disorder	6.76e-06	3.19e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—CAT—autistic disorder	6.67e-06	3.14e-05	CbGpPWpGaD
Naloxone—CREB1—Disease—IL6—autistic disorder	6.66e-06	3.14e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—PTEN—autistic disorder	6.53e-06	3.07e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—SERPINE1—autistic disorder	6.42e-06	3.03e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—CACNA1C—autistic disorder	6.4e-06	3.02e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—MTHFR—autistic disorder	6.39e-06	3.01e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—MTHFR—autistic disorder	6.35e-06	2.99e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—PLA2G4A—autistic disorder	6.29e-06	2.96e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—GSTM1—autistic disorder	6.29e-06	2.96e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling by GPCR—HRAS—autistic disorder	6.1e-06	2.87e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—MAPK1—autistic disorder	6.07e-06	2.86e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—MAPK1—autistic disorder	6.05e-06	2.85e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—GPX1—autistic disorder	6.03e-06	2.84e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—APOE—autistic disorder	5.95e-06	2.8e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—APOE—autistic disorder	5.91e-06	2.78e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—IL2—autistic disorder	5.86e-06	2.76e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling by GPCR—IL6—autistic disorder	5.83e-06	2.75e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—DHFR—autistic disorder	5.82e-06	2.74e-05	CbGpPWpGaD
Naloxone—ALB—Hemostasis—HRAS—autistic disorder	5.69e-06	2.68e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—MTHFR—autistic disorder	5.56e-06	2.62e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—PTEN—autistic disorder	5.52e-06	2.6e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—PIK3CG—autistic disorder	5.37e-06	2.53e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—PIK3CG—autistic disorder	5.33e-06	2.51e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—MAPK1—autistic disorder	5.31e-06	2.5e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—IL2—autistic disorder	5.2e-06	2.45e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—APOE—autistic disorder	5.18e-06	2.44e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—POMC—autistic disorder	5.11e-06	2.41e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—POMC—autistic disorder	5.08e-06	2.39e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—PTEN—autistic disorder	4.89e-06	2.3e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—HRAS—autistic disorder	4.87e-06	2.3e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—HRAS—autistic disorder	4.86e-06	2.29e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—PIK3CG—autistic disorder	4.67e-06	2.2e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—IL6—autistic disorder	4.66e-06	2.2e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—IL6—autistic disorder	4.65e-06	2.19e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—CYP19A1—autistic disorder	4.56e-06	2.15e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—MAPK1—autistic disorder	4.48e-06	2.11e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—POMC—autistic disorder	4.45e-06	2.1e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—HRAS—autistic disorder	4.26e-06	2.01e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—COMT—autistic disorder	4.24e-06	2e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—GSTP1—autistic disorder	4.22e-06	1.99e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—MAOA—autistic disorder	4.21e-06	1.98e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—CAT—autistic disorder	4.11e-06	1.93e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—IL6—autistic disorder	4.08e-06	1.92e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—PTGS2—autistic disorder	4.07e-06	1.92e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—PTGS2—autistic disorder	4.05e-06	1.91e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—MAPK1—autistic disorder	3.98e-06	1.87e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—PLA2G4A—autistic disorder	3.88e-06	1.83e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—GSTM1—autistic disorder	3.88e-06	1.83e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—GPX1—autistic disorder	3.71e-06	1.75e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—HRAS—autistic disorder	3.6e-06	1.7e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—PTEN—autistic disorder	3.55e-06	1.67e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—PTGS2—autistic disorder	3.55e-06	1.67e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—PTEN—autistic disorder	3.53e-06	1.66e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—IL6—autistic disorder	3.45e-06	1.62e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—MTHFR—autistic disorder	3.43e-06	1.61e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—HRAS—autistic disorder	3.19e-06	1.5e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—APOE—autistic disorder	3.19e-06	1.5e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—PTEN—autistic disorder	3.09e-06	1.46e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—IL6—autistic disorder	3.06e-06	1.44e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—PIK3CG—autistic disorder	2.88e-06	1.36e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—POMC—autistic disorder	2.74e-06	1.29e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—PTGS2—autistic disorder	2.19e-06	1.03e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—PTEN—autistic disorder	1.91e-06	8.98e-06	CbGpPWpGaD
